Vetigenics Advances Precision Immunotherapy for Pets
Vetigenics is working to change how serious diseases in pets are treated. The company combines deep science with a clear focus on real clinical needs in dogs and cats.
Cancer and chronic immune driven diseases remain major challenges in companion animal health. In contrast to human medicine, veterinary care still relies heavily on adapted human drugs. These treatments often fail to match animal biology and can limit safety and effectiveness.
Vetigenics was created to close this gap.
A Species-Specific Approach to Animal Health
Vetigenics is a clinical stage animal health biotech company. It develops antibody based immunotherapies designed specifically for dogs and cats.
Rather than adapting human medicines, the company builds therapies from the ground up for each species. This approach improves safety, tolerability, and quality of life for animal patients.
As a result, treatments better match how canine and feline immune systems actually work.
The CANIBODY Platform Built for Veterinary Medicine
At the core of Vetigenics’ work is the CANIBODY Discovery Platform. This proprietary system uses a fully canine phage display library.
Because the antibodies come from real dogs, they fit naturally with the canine immune system. This reduces the risk of immune reactions that can limit long-term use.
At the same time, Vetigenics is developing a species aware strategy to support future feline therapies.
Faster and Safer Antibody Discovery
The CANIBODY platform acts as a repeatable discovery engine. It shortens the path from target to lead candidate.
Key strengths include:
- Antibodies derived from naturally occurring canine immune responses
- Rapid discovery of high affinity, target-specific antibodies
- Early optimisation to improve stability and manufacturability
- Lower risk of immunogenicity during long-term treatment
Together, these features save time and reduce development costs.
Leading Progress in Veterinary Immuno-Oncology
Vetigenics has become a leader in veterinary immuno-oncology. Cancer remains a leading cause of death in older dogs and cats.
Current options often rely on chemotherapy. While it can help, side effects are common, and survival gains are limited.
Vetigenics takes a different path. Its therapies aim to activate the animal’s own immune system to recognise and attack cancer cells. Similar approaches have transformed outcomes in human care.
The company aims to bring those benefits to veterinary patients.
Expanding Beyond Cancer Treatment
In addition to oncology, Vetigenics is building a broad antibody pipeline. Focus areas include autoimmune disease, allergy, and osteoarthritis.
These targeted biologics offer better specificity and long-term disease control. Over time, they could redefine standards of care in veterinary medicine.
A Companion-Animal-First Development Model
Vetigenics follows a development model inspired by translational medicine. Dogs naturally develop many of the same diseases as humans.
They share environments, face similar immune challenges, and receive care in real clinical settings. This makes them highly relevant patients for studying disease biology.
While Vetigenics does not conduct human trials, it applies insights from human research to guide animal therapies.
Working Closely With the Veterinary Community
The company runs preclinical studies and clinical trials in pet dogs and cats. It works closely with veterinarians, oncologists, academic groups, and industry partners.
Through these collaborations, Vetigenics can:
- Design studies that reflect everyday veterinary practice
- Use patient derived samples to generate meaningful data
- Include clinician and owner input in trial design
This helps move therapies from discovery to real world impact faster.
Overcoming Challenges in Veterinary Drug Development
Veterinary biotech faces unique hurdles. These include smaller study populations, limited reagents, and different regulatory pathways.
Vetigenics addresses these issues directly. It invests in canine-specific assays, biomarkers, and immune monitoring tools.
Owner trust also matters. Clear communication around study goals and sample use helps build confidence among veterinarians and pet owners alike.
Shaping the Future of Precision Pet Medicine
Looking ahead, Vetigenics sees precision medicine as a core part of veterinary care.
Future priorities include:
- Expanding the antibody pipeline in high-need areas
- Using biomarkers to guide treatment decisions
- Developing practical and cost-effective delivery methods
Strategic partnerships will support growth and help bring new therapies to market.
A Mission Focused on Better Lives for Pets
Vetigenics is driven by a simple mission. Help pets live healthier, longer, and happier lives.
This mission guides every stage of development, from early discovery to clinical care. Through science, collaboration, and purpose, Vetigenics aims to set a new standard for companion animal medicine.
